Cited by 270Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and CancerBiochemical and Molecular Research

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases in cancer metabolism

Open access
Ros, Susana, Schulze, Almut·2013·Cancer & Metabolism

Abstract

The increased glucose metabolism in cancer cells is required to fulfill their high energetic and biosynthetic demands. Changes in the metabolic activity of cancer cells are caused by the activation of oncogenes or loss of tumor suppressors. They can also be part of the metabolic adaptations to the conditions imposed by the tumor microenvironment, such as the hypoxia response. Among the metabolic enzymes that are modulated by these factors are the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases (PFKFBs), a family of bifunctional enzymes that control the levels of fructose 2,6-bisphosphate (Fru-2,6-P2). This metabolite is important for the dynamic regulation of glycolytic flux by allosterically activating the rate-limiting enzyme of glycolysis phosphofructokinase-1 (PFK-1). Therapeutic strategies designed to alter the levels of this metabolite are likely to interfere with the metabolic balance of cancer cells, and could lead to a reduction in cancer cell proliferation, invasiveness and survival. This article will review our current understanding of the role of PFKFB proteins in the control of cancer metabolism and discuss the emerging interest in these enzymes as potential targets for the development of antineoplastic agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/2049-3002-1-8

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 PFK-2/FBPase-2 control of glycolysis and gluconeogenic pathways. Overview of glycolysis and gluconeogenesis. Enzymes: phosphofructokinase (PFK-1), fructose 1,6-bisphosphatase (FBPase), 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases (PFK-2/FBPase-2), pyruvate kinase (PK). Fructose 2,6-bisphosphate is an activator of PFK-1 and inhibitor of FBPase. Fructose 1,6-bisphosphate is an activator of PK. The rest of the enzymes and cofactors have been omitted for simplicity.
Figure 1 PFK-2/FBPase-2 control of glycolysis and gluconeogenic pathways. Overview of glycolysis and gluconeogenesis. Enzymes: phosphofructokinase (PFK-1), fructose 1,6-bisphosphatase (FBPase), 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases (PFK-2/FBPase-2), pyruvate kinase (PK). Fructose 2,6-bisphosphate is an activator of PFK-1 and inhibitor of FBPase. Fructose 1,6-bisphosphate is an activator of PK. The rest of the enzymes and cofactors have been omitted for simplicity.CC BY · PubMed Central
Figure 2 Relative activity of 6-phosphofructo-2-kinase (PFK-2)/fructose 1,6-bisphosphatase (FBPase-2). Properties of the PFK-2/FBPase-2 enzymes. Information on chromosomal location and relative enzymatic activity of the different isoforms has been taken from Okar et al. Trends BiochemSci (2001) [7].
Figure 2 Relative activity of 6-phosphofructo-2-kinase (PFK-2)/fructose 1,6-bisphosphatase (FBPase-2). Properties of the PFK-2/FBPase-2 enzymes. Information on chromosomal location and relative enzymatic activity of the different isoforms has been taken from Okar et al. Trends BiochemSci (2001) [7].CC BY · PubMed Central
Figure 3 Domain organizations and phosphorylation of 6-phosphofructo-2-kinase (PFK-2)/fructose 1,6-bisphosphatase (FBPase-2) isoenzymes. The N-terminal PFK-2 domain is shown in red, the C-terminal FBPase-2 domain is shown in blue and the regulatory domains are shown in green. Phosphorylation sites and the kinases responsible of their phosphorylation are indicated on each main isoforms. The domain structure of human PFK-2/FBPase-2 enzymes is based on Rider et al. Biochem J (2014) [10].
Figure 3 Domain organizations and phosphorylation of 6-phosphofructo-2-kinase (PFK-2)/fructose 1,6-bisphosphatase (FBPase-2) isoenzymes. The N-terminal PFK-2 domain is shown in red, the C-terminal FBPase-2 domain is shown in blue and the regulatory domains are shown in green. Phosphorylation sites and the kinases responsible of their phosphorylation are indicated on each main isoforms. The domain structure of human PFK-2/FBPase-2 enzymes is based on Rider et al. Biochem J (2014) [10].CC BY · PubMed Central
Figure 4 Role of 6-phosphofructo-2-kinase (PFK-2)/fructose 1,6-bisphosphatase (FBPase)-2 in the balance between glycolytic flux and redox regulation. Glucose-6-phosphate fulfills glycolysis, glycogen synthesis and pentose phosphate pathways. The scheme shows how the PFK-2 or the FBPase-2 activity could be crucial in controlling the balance between glycolytic flux and redox regulation by the pentose phosphate pathway for nicotinamide adenine dinucleotide phosphate (NADPH) production. Enzymes: phosphofructokinase (PFK-1), phosphofructokinase 2/fructose 2,6-bisphosphatase (PFK-2/FBPase-2), TIGAR (FBPase-2 activity). Fructose 2,6-bisphosphate is an activator of PFK-1 and inhibitor of FBPase.
Figure 4 Role of 6-phosphofructo-2-kinase (PFK-2)/fructose 1,6-bisphosphatase (FBPase)-2 in the balance between glycolytic flux and redox regulation. Glucose-6-phosphate fulfills glycolysis, glycogen synthesis and pentose phosphate pathways. The scheme shows how the PFK-2 or the FBPase-2 activity could be crucial in controlling the balance between glycolytic flux and redox regulation by the pentose phosphate pathway for nicotinamide adenine dinucleotide phosphate (NADPH) production. Enzymes: phosphofructokinase (PFK-1), phosphofructokinase 2/fructose 2,6-bisphosphatase (PFK-2/FBPase-2), TIGAR (FBPase-2 activity). Fructose 2,6-bisphosphate is an activator of PFK-1 and inhibitor of FBPase.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Cited by

Sorted by citations

Items 201–270 of 270

Metadata

Authors
Ros, S., & Schulze, A.
Affiliations
Cancer Research UK (GB)
Corresponding author
Schulze, Almut
Venue
Cancer & Metabolism
Published
2013-02-04
Volume
1
Issue
1
Pages
8-8
ISSN
2049-3002 (ISSN-L)
OpenAlex
W2106223802
Cited by
269
References
69
Citations by year
2026: 9 · 2025: 21 · 2024: 29 · 2023: 32 · 2022: 31 · 2021: 26 · 2020: 15 · 2019: 20 · 2018: 17 · 2017: 17 · 2016: 19 · 2015: 20 · 2014: 11 · 2013: 2
FWCI
6.22
Type
journal article
Language
en
Open access
Locations
  • Cancer & Metabolism (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
Funders
Cancer Research UK
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
Keywords
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase, fructose-2,6-bisphosphate, glycolytic flux, tumor microenvironment, hypoxia response, oncogene activation, tumor suppressor loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review